If you have been reading about thymalfasin and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-05-27. Numbers and descriptions here follow the published literature rather than marketing material.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography, which separates the peptide from closely related impurities and from truncated or oxidized variants. Mass spectrometry supplies the molecular mass and confirms the expected sequence length, while amino acid analysis can be used to check composition. Because the molecule has no chromophore beyond the peptide backbone, ultraviolet detection is typically performed at a low wavelength, where baseline interference from solvents and buffers is a practical concern. Water content and counter-ion content are often reported alongside purity.
Practical handling focuses on limiting adsorption and contamination. The peptide dissolves readily in water, and dilute solutions tend to adhere to plastic and glass surfaces, so an inert carrier protein or a defined buffer can reduce losses in laboratory work. Workers also record the counter-ion form, since an acetate or trifluoroacetate salt changes the mass balance of the weighed powder. Documentation of lot number, purity value, and storage history supports reproducibility when results from different laboratories are compared.
Lyophilized material is generally held at reduced temperature to slow degradation, and storage at minus twenty degrees Celsius or lower is common practice for long-term retention. Short-term working portions are often kept between two and eight degrees Celsius. Once dissolved, the peptide is less stable than the dry powder, and repeated freeze-thaw cycles are associated with loss of material and with aggregate formation. Vials are usually allowed to reach room temperature before opening so that condensation does not introduce moisture, and solutions are protected from light where practical.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Lyophilized thymosin alpha-1 is generally stored at or below minus twenty degrees Celsius, protected from moisture and light. Short-term handling at ambient temperature is possible for dry powder, but reconstituted solutions degrade faster and are usually kept at two to eight degrees Celsius with a defined expiry of days rather than weeks. Repeated freeze-thaw cycles should be avoided because they promote aggregation and loss of potency. Exact limits depend on the formulation and should follow the supplier's documentation.
Identity and purity are normally assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and truncation products. Mass spectrometry confirms molecular mass and detects modifications such as deamidation or oxidation. Amino acid analysis and peptide mapping provide additional sequence-level confirmation. For research material, a certificate of analysis typically reports these results together with water content and counter-ion identity, since the lyophilized powder is often supplied as an acetate or trifluoroacetate salt.
Several factors accelerate degradation: alkaline pH, elevated temperature, exposure to oxidants, and the presence of residual moisture. Deamidation of asparagine residues and oxidation of methionine are the most commonly reported degradation routes. Because the peptide lacks disulfide bonds, it does not undergo the thiol-related aggregation seen in some other biologics, but physical aggregation can still occur at high concentration. Stability data are product-specific, and extrapolating shelf life between formulations is not reliable.
== Occurrence == Realgar most commonly occurs as a low-temperature hydrothermal vein mineral associated with other arsenic and antimony minerals. It also occurs as volcanic sublimations and in hot spring deposits. It occurs in association with orpiment, arsenolite, calcite and barite. It is found with lead, silver and gold ores in Hungary, Bohemia and Saxony. In the US it occurs notably in Mercur, Utah; Manhattan, Nevada; and in the geyser deposits of Yellowstone National Park. After a long period of exposure to light, realgar changes form to a yellow powder known as pararealgar (β-As4S4). It was once thought that this powder was the yellow sulfide (orpiment), but is a distinct chemical compound.
The hydrogen bond criterion for beta turns, applied to polypeptides whose amino acids are linked by trans peptide bonds, gives rise to just four categories, as shown by Venkatachalam in 1968. They are called types I, II, I' and II'. All occur regularly in proteins and polypeptides but type I is most common, because it most resembles an alpha helix, occurring within 310 helices and at the ends of some classic alpha helices. Type II beta turns, on the other hand, often occur in association with beta-sheet as part of beta-links. The four types of beta turn are distinguished by the φ, ψ angles of residues i+1 and i+2 as shown in the table below giving the typical average values. Glycines are especially common as amino acids with positive φ angles; for prolines such a conformation is sterically impossible but they occur frequently at amino acid positions where φ is negative.
== Personal life == In the early 1990s, Staley enrolled in several rehab programs, but he failed to stay clean for long. At one point, the other members of Alice in Chains flew to Los Angeles for weekly therapy at Staley's rehab. During the Dirt tour, Alice in Chains' manager, Susan Silver, hired bodyguards to keep Staley away from people who might try to pass him drugs, but he ended up relapsing on alcohol and drugs during the tour. Screaming Trees' Mark Lanegan recalled partying with Staley on tour and said that, "off stage, it was an insane, dark, drug and alcohol-fuelled frat party from start to finish, with Layne [Staley] and I raising hell, behaving like teenagers, staying up for days on end. We partook of whatever drugs came our way. Heroin, cocaine, painkillers, anything." Kurt Cobain's death in April 1994 scared Staley into temporary sobriety, but soon he was back into his addiction. Alice in Chains' managers turned down lucrative touring possibilities and kept the band off the road, hoping that would help Staley. Pearl Jam lead guitarist Mike McCready also tried to help Staley by inviting him to his side project, Mad Season. McCready had hoped that playing with sober musicians would encourage Staley. On October 29, 1996, Staley's former fiancée, Demri Lara Parrott, died of a drug overdose. Staley was placed on a 24-hour suicide watch, according to NME, which quoted a friend saying Staley was taking Parrott's death "extremely badly" and had fallen into a deep depression. Lanegan told Rolling Stone in 2002, "He never recovered from Demri's death.
== Talent == Global Talent Competitiveness Index (GTCI) 2018: The report analyses the performance of 119 countries and 90 cities worldwide based on six factors: enabling talent, attracting talent, growing talent, retaining talent, vocational and technical skills, and global knowledge skills. Thailand ranked 70 of 119 countries (1=best; 119=worst). Other ASEAN nations ranked were: Singapore, 2; Philippines, 54; Indonesia, 77; Vietnam, 87; Laos, 95; and Cambodia, 108. Bangkok ranked 78 of 90 cities. Global Talent Competitiveness Index (GTCI) 2017: Thailand ranked 73 of 118 countries (1=best; 118=worst). Other ASEAN nations were ranked: Singapore, 2; Malaysia, 28; Philippines, 52; Vietnam, 86; Indonesia, 90; and Cambodia, 108. IMD World Talent Report 2016: This study purports to measure investment in and development of talent and the ability to attract and retain talent. Thailand ranked 37 of 61 nations (1=best; 61=worst), down three spots from 2015. Other ASEAN nations were ranked: Singapore, 15; Malaysia, 19; Indonesia, 44; Philippines, 51.
Sources: en.wikipedia.org
Purification of the crude synthesis solution increases usability of the products by improving the chances of successfully obtaining full-length oligo sequences. Successfully synthesized long oligo-sequences are scarce; the solution predominantly contains truncated or failed oligo-sequences. By tagging only full-length oligonucleotides with polymerizable tagging phosphoramidite (PTP) and incorporating them into polyacrylamide gel, truncated, or untagged, sequences are washed away, and the desired sequences are retained. This purification method is coined catching-by-polymerization (CBP) and allows for successful recovery of synthesized sequences. Utilizing these methods, successful direct chemical synthesis of ultra-long (800-mer and 1728-mer) oligonucleotides has been achieved.
Although eating tainted beef can lead to New Variant Creutzfeldt-Jakob disease (the human variant of mad-cow disease, bovine spongiform encephalopathy), there is no known case of BSE having been transmitted through collagen products such as gelatine.
== History == Doxepin was discovered in Germany in 1963 and was introduced in the United States as an antidepressant in 1969. It was subsequently approved at very low doses in the United States for the treatment of insomnia in 2010.
By the end of 2021, 40 of his nominees to the federal judiciary had been confirmed, more than any president in his first year in office since Ronald Reagan. Biden prioritized diversity in his judicial appointments more than any president in U.S. history, with most of his appointees being women and people of color. In January 2022, Supreme Court justice Stephen Breyer announced his intention to retire. During his 2020 campaign, Biden vowed to nominate the first Black woman to the Supreme Court if a vacancy occurred, a promise he reiterated after Breyer announced his retirement. On February 25, Biden nominated federal judge Ketanji Brown Jackson. She was sworn in on June 30. By the end of his presidency, Biden had appointed 235 judges, more appointments in a single term than any other president in at least 50 years. 63% of Biden's judges were women and 60% were non-white. Biden expressed interest in judicial term limits and a binding ethics code for Supreme Court justices.
The National Association of State Mental Health Program Directors said that antipsychotics are not interchangeable, and it recommends including trying at least one weight-neutral treatment for those patients with potential metabolic issues. Subtle, long-lasting forms of akathisia are often overlooked or confused with post-psychotic depression, in particular when they lack the extrapyramidal aspect that psychiatrists have been taught to expect when looking for signs of akathisia. Adverse effect on cognitive function and increased risk of death in people with dementia along with worsening of symptoms has been described in the literature. Antipsychotics, due to acting as dopamine D2 receptor antagonists and thereby stimulating pituitary lactotrophs, may have a risk of prolactinoma with long-term use. This is also responsible for their induction of hyperprolactinemia (high prolactin levels).
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
Cool storage below freezing is usual for long-term retention, with a desiccant and protection from light. Portions are often split before first use to avoid repeated handling.